Table 1 Demographic and clinical characteristics of patients with high-risk and non high-risk prostate cancer.
Parameter | High risk prostate cancer | Non high-risk prostate cancer | P value |
|---|---|---|---|
Total Patients (n) | 251 | 434 | |
Median Age (IQR) | 63.00 (8.20) | 62.90 (8.60) | 0.290 |
Median PSA (IQR) | 11.90 (12.00) | 8.00 (4.56) | <0.001 |
Mean Charlson Comorbidity Index (IQR) | 0 (1) | 0 (1) | 0.812 |
Median Tumour Volume (IQR) | 3.60 (5.45) | 1.93 (2.55) | <0.0001 |
Median No. of Weeks follow-Up (IQR) | 232.00 (310.00) | 258.50 (275.70) | 0.372 |
Median Specimen Size (IQR) | 41.00 (21.00) | 40.00 (19.00) | 0.144 |
Patients with Neoadjuvant Treatment (ADT and/or Radiotherapy) (%) | 63 (25.10%) | 19 (4.38%) | <0.001 |
Pathological Grade Group, n (%) | |||
1 | 7 (2.79) | 70 (16.13) | <0.001 |
2 | 104 (41.43) | 280 (64.52) | |
3 | 86 (34.26) | 75 (17.28) | |
4 | 12 (4.78) | 4 (0.92) | |
5 | 42 (16.73) | 5 (1.15) | |
Pathological T Stage, n (%) | |||
T2a | 12 (4.78) | 17 (3.933) | <0.001 |
T2b | 3 (1.20) | 8 (1.85) | |
T2c | 64 (25.50) | 258 (59.58) | |
T3a | 113 (45.02) | 114 (26.33) | |
T3b | 54 (21.51) | 32 (7.39) | |
T4 | 5 (1.99) | 4 (0.92) | |
Biochemical Recurrence, n (%) | 137 (54.58) | 147 (33.87) | <0.001 |
Failure Free Survival, n (%) | 132 (52.59) | 314 (72.35) | <0.001 |
